Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lotamilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lotamilast SCHEMBL369445 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL12513023 | 0.93 | PDE4A (0.88) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL297387 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL12513345 | 0.93 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL296279 | 0.92 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL1942703 | 0.92 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL1942230 | 0.92 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL296765 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL12513255 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DCTNNB1 | |
| SCHEMBL1940196 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| US-11504332-B2 | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof | VK RESEARCH ASSOCIATES INC. (US) | 2022-11-22 | — | — | US | claimed |
| US-20220304935-A1 | PHOSPHODIESTERASE-4 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | VK Research Associates Inc | 2022-09-29 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| CN-109982701-B | Application of SERD (serine-transferase) and CDK4/6 inhibitor and PI3K/mTOR pathway inhibitor | 江苏恒瑞医药股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260014156-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | BT BIDCO INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025100865-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PSORIASIS AND ATOPIC DERMATITIS | 장병모 | 2025-05-15 | — | — | WO | disclosed |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12171764-B2 | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor | BIORA THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
| EP-3959213-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3958969-A1 | ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-11241485-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022022669-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 12/4885 |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, PKD1, PKD2 | PDE4A 388/4885PDE4B 776/4885PDE4C 841/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | PDE4A 287/4885PDE4B 313/4885PDE4C 554/4885 |
| US-20260014156-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK OR OTHER KINASE INHIBITOR | JAK1, JAK3, JAK2 | PDE4A 1739/4885PDE4B 2104/4885PDE4C 2134/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4C 1570/4885 |
| US-12171764-B2 | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor | JAK3, JAK1, JAK2 | PDE4A 1721/4885PDE4B 1931/4885PDE4C 2355/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE4A 1073/4885PDE4B 1894/4885PDE4C 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.